AMENDMENTS TO THE CLAIMS

1.-24. **(Canceled)**

25. **(Original)** A prosthesis for placement at an Os opening from a main body lumen to a branch body lumen; the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen; and

a plurality of fronds extending axially from an end of the support, the fronds configured to be deformably deployed in at least a portion of the main body lumen and to apply less radial force to adjacent tissue than the expanded support applies in the branch body lumen.

26.-29. **(Canceled)**

30. **(New)** The prosthesis of Claim 25, wherein the plurality of fronds includes at least three fronds.

31. **(New)** The prosthesis of Claim 25, wherein the plurality of fronds comprises a helical configuration.

32. **(New)** The prosthesis of Claim 31, comprising a plurality of helical fronds.

33. **(New)** The prosthesis of Claim 25, wherein at least a portion of the plurality of fronds comprises a lubricous coating.

34. **(New)** The prosthesis of Claim 25, comprising an endothelial cell ingrowth surface.

35. **(New)** The prosthesis of Claim 25, comprising a non thrombogenic surface.

36. **(New)** The prosthesis of Claim 25, further comprising a circumferential link that connects each of the plurality of fronds.

37. **(New)** The prosthesis of Claim 36, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(New)** The prosthesis of Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(New)** The prosthesis of Claim 37, wherein the drug is one of an anti-cell prolifertive, anti cell migration, anti-neo plastic, anti inflammatory drug.

40. **(New)** The prosthesis of Claim 37, wherein the drug is configured to reduce an incidence or amount of restensosis.

41. **(New)** The prosthesis of Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(New)** The prosthesis of Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(New)** The prosthesis of Claim 36, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

44. **(New)** The prosthesis of Claim 36, wherein the support is on a first end of at least one of the fronds, and the circumferential link is on a second end of at least one of the fronds.

45. **(New)** The prosthesis of Claim 36, wherein the circumferential link is radiopaque.

46. **(New)** The prosthesis of Claim 36, wherein the circumferential link has a greater radiopacity than the frond.